Latest News About Hantavirus Pulmonary Syndrome

Here’s the latest on Hantavirus Pulmonary Syndrome (HPS) based on publicly available health sources as of May 2026.

Direct answer

• There is no widely available vaccine or specific antiviral treatment for HPS; care is primarily supportive in intensive care settings, with oxygenation and hemodynamic support being critical. Early recognition and rapid escalation to advanced supportive measures, including ECMO in select cases, are associated with better outcomes. The Andes virus, a South American strain, remains a particular concern due to its potential for human-to-human transmission in rare circumstances, though transmission is generally linked to rodent exposure rather than person-to-person spread.[2][3][8][9]

Key context and nuances

• Epidemiology: HPS typically results from exposure to infected rodent excreta and is characterized by a brief prodrome followed by rapid progression to respiratory failure; the time from symptom onset to severe disease can be short, often within 4–24 hours once respiratory symptoms begin.[3][2]
• Clinical management: There is no licensed antiviral proven to alter the course of HPS; management focuses on aggressive supportive care, including mechanical ventilation and in severe cases ECMO, alongside meticulous fluid management to avoid worsening pulmonary edema.[2][3]
• Public health surveillance: Reports indicate clustered outbreaks and ongoing surveillance by CDC/WHO, with special attention to the MV Hondius cruise-ship-linked exposures in 2025–2026 and broader rodent-borne risk in endemic regions.[5][9][2]

What this means for travelers and residents near risk areas

• Minimize exposure to rodent-infested environments; use proper precautions when cleaning areas with potential rodent activity (wetting down dust and wearing protective gear).
• If you develop flu-like symptoms after rodent exposure or potential exposure events in the past 1–8 weeks, seek prompt medical evaluation, especially if you experience fever, fatigue, muscle aches, or shortness of breath, since early care improves outcomes.[9][3]

Illustrative note

• The current consensus emphasizes supportive care and EC MO where feasible, with about a third to nearly half of severe cases historically progressing to fatal outcomes without advanced support; outcomes improve with timely ICU admission and access to ECMO in experienced centers.[3][2]

Cited sources

• Hantavirus Pulmonary Syndrome treatment and the lack of specific antiviral therapy; emphasis on supportive care and ECMO in severe cases.[3]
• CDC and surveillance updates on HPS outbreaks and clinical management considerations; notes on exposure, progression, and the role of ECMO.[9][2]
• General epidemiology and pathophysiology, including rodent exposure as the primary transmission route and the rapid progression once pulmonary involvement begins.[2][3]

If you’d like, I can pull more targeted updates (for example, country-specific alerts or hospital guidance) or summarize the latest data on ECMO outcomes in HPS patients.